4Kscore 测试在前列腺癌主动监测中预测肿瘤重新分级的作用
本研究基于西班牙主动监测国家注册研究,纳入 137 例低风险前列腺癌患者,评估 4Kscore 在 6 个月确认活检时预测肿瘤重新分级(Grade group ≥2)的能力。结果显示 18 例(13.1%)发生重新分级,4Kscore 和 %f/t PSA 比值在重新分级组间有差异;以 7.5% 为 cutoff,敏感性 89%、特异性 29%,可减少 27% 的活检,但漏诊 2 例(6%)Grade group 2。
要点
- 4Kscore 可能辅助决定主动监测中是否行确认活检。
- 以 7.5% 为 cutoff 可减少 27% 活检,但特异性仅 29%。
- 4Kscore 低于 7.5% 者无 Grade group 3 重新分级,但漏诊 6% Grade group 2。
核心结论
- 4Kscore 可能有助于主动监测中决定是否进行确认活检。
研究设计与样本
- 观察性、前瞻性、盲法、非随机研究,基于西班牙主动监测国家注册研究(AEU/PIEM/2014/0001;NCT02865330),初始活检后纳入 181 例,137 例符合纳入标准。
主要发现
- 137 例中 18 例(13.1%)在确认活检时发生重新分级(Grade group ≥2)。
- 4Kscore 和 %f/t PSA 比值在重新分级组与未重新分级组间有差异。
- 以 7.5% 为 4Kscore cutoff,敏感性 89%、特异性 29%,活检减少 27%。
- 4Kscore 低于 7.5% 者无 Grade group 3 重新分级,但漏诊 2 例(6%)Grade group 2 重新分级。
- 4Kscore 也与肿瘤体积变化相关。
关键数值与推荐
- 纳入标准:PSA ≤10 ng/mL、cT1c-T2a、Grade group 1、阳性针数 ≤2、受累针长 ≤5 mm 或 ≤50%。
- 重新分级定义为确认活检 Grade group ≥2。
- 4Kscore cutoff 7.5%:敏感性 89%、特异性 29%、活检减少 27%、漏诊 Grade group 2 为 6%。
临床怎么用
- 对于低风险前列腺癌主动监测患者,可考虑检测 4Kscore 辅助决策确认活检。
- 4Kscore 低于 7.5% 时虽无 Grade group 3 重新分级,但仍需注意 6% Grade group 2 漏诊风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Management of active surveillance (AS) in low-risk prostate cancer (PCa) patients could be improved with new biomarkers, such as the 4Kscore test. We analyze its ability to predict tumor reclassification by upgrading at the confirmatory biopsy at 6 months. METHODS: Observational, prospective, blinded, and non-randomized study, within the Spanish National Registry on AS (AEU/PIEM/2014/0001; NCT02865330) with 181 patients included after initial Bx and inclusion criteria: PSA ≤10 ng/mL, cT1c-T2a, Grade group 1, ≤2 cores, and ≤5 mm/50% length core involved. Central pathological review of initial and confirmatory Bx was performed on all biopsy specimens. Plasma was collected 6 months after initial Bx and just before confirmatory Bx to determine 4Kscore result. In order to predict reclassification defined as Grade group ≥2, we analyzed 4Kscore, percent free to total (%f/t) PSA ratio, prostate volume, PSA density, family history, body mass index, initial Bx, total cores, initial Bx positive cores, initial Bx % of positive cores, initial Bx maximum cancer core length and initial Bx cancer % involvement. Wilcoxon rank-sum test, non-parametric trend test or Fisher's exact test, as appropriate established differences between groups of reclassification. RESULTS: A total of 137 patients met inclusion criteria. Eighteen patients (13.1%) were reclassified at confirmatory Bx. The %f/t PSA ratio and 4Kscore showed differences between the groups of reclassification (Yes/No). Using 7.5% as cutoff for the 4Kscore, we found a sensitivity of 89% and a specificity of 29%, with no reclassifications to Grade group 3 for patients with 4Kscore below 7.5% and 2 (6%) missed Grade group 2 reclassified patients. Using this threshold value there is a biopsy reduction of 27%. Additionally, 4Kscore was also associated with changes in tumor volume. CONCLUSIONS: Our preliminary findings suggest that the 4Kscore may be a useful tool in the decision-making process to perform a confirmatory Bx in active surveillance management.
引用
- Borque-Fernando Á, Rubio-Briones J, Esteban LM, et al. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2018. PMID: 30108375. doi:10.1038/s41391-018-0074-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。